About: Thalidomide     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] (en)
http://linked.open...y/drugbank/dosage
http://linked.open...gy/drugbank/group
  • approved (en)
  • withdrawn (en)
  • investigational (en)
http://linked.open...drugbank/halfLife
  • The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing. (en)
http://linked.open...ugbank/indication
  • For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. (en)
sameAs
Title
  • Thalidomide (en)
adms:identifier
http://linked.open...mechanismOfAction
  • In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor. (en)
http://linked.open...drugbank/packager
http://linked.open...y/drugbank/patent
http://linked.open...outeOfElimination
  • Thalidomide itself has less than 0.7% of the dose excreted in the urine as unchanged drug. (en)
http://linked.open.../drugbank/synonym
  • Thalidomide (en)
  • Distaval (en)
  • Pro-ban M (en)
  • Sedalis (en)
  • Softenon (en)
  • Talimol (en)
  • N-Phthaloylglutamimide (en)
  • N-Phthalylglutamic acid imide (en)
  • (+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide (en)
  • (+-)-Thalidomide (en)
  • (±)-N-(2,6-dioxo-3-piperidyl)phthalimide (en)
  • (±)-thalidomide (en)
  • 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline (en)
  • 2,6-dioxo-3-phthalimidopiperidine (en)
  • 3-Phthalimidoglutarimide (en)
  • K-17 (en)
  • N-(2,6-dioxo-3-piperidyl)phthalimide (en)
  • N-Phthalyl-glutaminsaeure-imid (en)
  • Talidomida (en)
  • Thalidomidum (en)
  • alpha-(N-Phthalimido)glutarimide (en)
  • alpha-N-Phthalylglutaramide (en)
  • alpha-Phthalimidoglutarimide (en)
  • α-(N-phthalimido)glutarimide (en)
  • α-N-phthalylglutaramide (en)
  • α-phthalimidoglutarimide (en)
http://linked.open...drugbank/toxicity
  • The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD<sub>50</sub> could not be established in mice for racemic thalidomide, whereas LD<sub>50</sub> values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively. (en)
http://linked.open...nk/proteinBinding
  • 55% and 66% for the (+)R and (&minus;)S enantiomers, respectively. (en)
http://linked.open...ynthesisReference
  • Jamshed Shah, "Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs." U.S. Patent US20030139451, issued July 24, 2003. (en)
http://linked.open...y/mesh/hasConcept
foaf:page
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...l/drug/hasATCCode
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open...ugbank/absorption
  • The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen&rsquo;s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract. (en)
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 50-35-1 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...gbank/containedIn
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...ank/Melting-Point
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software